| Document |
Document Title |
|
WO/2012/048289A1 |
A non-synthetic, hydrophilic, biodegradable, biocompatible polysaccharide based non-toxic anti-adhesion hydrogel barrier is disclosed herein. The barrier of the present invention is formed by constructing a unique interpenetrating, cross...
|
|
WO/2012/030030A1 |
The present invention relates to a chitosan derivative having a visible-light-curing characteristic whereby it is cured by visible-light irradiation, and to a use for the same as a medical raw material. The chitosan derivative of the pre...
|
|
WO/2012/024072A1 |
The present specification discloses compositions and methods of transplanting tissue useful for treating a soft tissue condition of an individual.
|
|
WO/2012/021818A2 |
Provided herein are methods of treating central nervous system injury (e.g., spinal cord injury) using GGF2 and compositions comprising GGF2. For example, provided is a method of treating spinal cord injury in a subject, comprising admin...
|
|
WO/2012/018790A2 |
Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.
|
|
WO/2012/017449A1 |
The invention discloses novel 42-0-(heteroalkoxyalkyl) rapamycin compounds of formula (1) and process for preparation thereof. These compounds are useful in the treatment of hyperproliferative vascular diseases such as restenosis and ath...
|
|
WO/2012/002986A2 |
Compositions comprising decellularized and delipidized extracellular matrix derived from adipose or loose connective tissue, and therapeutic uses thereof. Methods for treating, repairing or regenerating defective, diseased, or damaged ad...
|
|
WO/2011/162633A1 |
The present invention relates to biology and medicine and in particular can be used in medicine for the preparation of a pharmaceutical composition for the specific, self-regulating uncoupling of mitochondria. The invention can be useful...
|
|
WO/2011/151731A2 |
Disclosed herein are surgical adjuvant compositions for ameliorating tissue and cellular necrosis and/or apoptosis. In addition, surgical methods are described which include the use of the adjuvant of the composition to reduce tissue and...
|
|
WO/2011/128424A1 |
The disclosed methods, uses and articles are in the field of orthopedic and dental implants. In particular, the disclosure relates to compositions and methods for improving the osseointegration of such implants.
|
|
WO/2011/123061A1 |
The present invention provides an amphiphilic linear peptide and/or peptoid as well as a hy-drogel that includes the amphiphilic linear peptide/peptoid. The amphiphilic linear pep-tide/peptoid is capable of forming a hydrogel. These pept...
|
|
WO/2011/121354A1 |
Tetrathiomolybdate is for use in therapy of a condition requiring reduced core temperature, e.g. ischemia-reperfusion injury.
|
|
WO/2011/109387A1 |
The invention discloses a method of treating cancer in a patient, comprising administering to the patient a radiation sensitizer selected from nitroimidazoles in an amount effective to sensitize a patient to radiation and subjecting the ...
|
|
WO/2011/055047A1 |
The invention relates to an aqueous composition used in the laser repair treatment of fibrous connective tissue, including: gold nanoparticles in a concentration of between 1.5 x 109 particles per ml and 1 x 1010 particles per ml; and al...
|
|
WO/2011/043739A1 |
The present invention relates to methods and compositions for the modulation of wound healing and/or the production of extracellular membrane components by modulating the activity and/or amount of secreted protein acidic and rich in cyst...
|
|
WO/2011/040888A1 |
The present invention provides a composition or combination comprising at least one biodegradable material for use in protecting and/or preserving cells. For example, the composition or combination of the invention may be for use in corn...
|
|
WO/2011/027706A1 |
Provided is a means for improving the solubility of a polysaccharide in water. Disclosed is a porous structure comprising a polysaccharide and having a plurality of pores, wherein the pores have an average pore diameter of 40 µm or larg...
|
|
WO/2011/011881A1 |
Compositions comprising fucan agents and the use of said compositions in the treatment, prevention, inhibition etc, of fibrous adhesions, peritonitis, ischemia, reperfusion injunry, endotoxemia, keloids and keloid trait scarring, dermati...
|
|
WO/2010/136589A1 |
Dry powder compositions are useful in the treatment or prevention of tissue adhesions during or after surgery or during wound therapy. The dry powder compositions may contain trehalose. The dry powder compositions may be fibrin sealant c...
|
|
WO/2010/125069A1 |
The present invention relates to compositions comprising high molecular weight hyaluronic acids. The compositions are useful for the reduction and/or prevention of formation of post surgical adhesions.
|
|
WO/2010/122787A1 |
Provided are a method for easily collecting a sufficient amount of peritoneal mesothelial cells and the collected peritoneal mesothelial cells. Also provided is a peritoneum-protecting agent which comprises said peritoneal mesothelial ce...
|
|
WO/2010/119994A1 |
Provided is a polysaccharide derivative resulting from substituting some of the carboxyl groups in a carboxy polysaccharide with –NH–X–CO–Y–Z. Also provided is a hydrogel thereof. Here, X represents a C1–10 hydrocarbon group,...
|
|
WO/2010/111137A2 |
A composition and method are described for suppressing or preventing fibrous adhesion formation using a multicomponent aqueous oxychlorine composition. Fibrous adhesions typically form during healing of tissue, for example following a su...
|
|
WO/2010/106519A1 |
The invention relates to a dose of 10 mg of AVE5026 for the treatment of venous thromboembolism in patients with severe renal impairment.
|
|
WO/2010/097595A1 |
The invention related to a composition for use in cardioplegia, said composition comprising (i) esmolol; and (ii) adenosine, wherein in use the concentration of said esmolol is in the range 0.3-1.5mM, and wherein in use the concentration...
|
|
WO/2010/095304A1 |
An impaired nervous function repairing agent including a hydrogel of a polysaccharide derivative that has a complex elastic modulus 1 to 1000 N/m2 and a loss coefficient of 0.01 to 2.0 calculated at an angular velocity of 10 rad/sec usin...
|
|
WO/2010/087521A1 |
Disclosed is a medicinal agent that enables the repair and regeneration of joint cartilages which have not been achieved by the conventional pharmaceutical preparations, is effective for the treatment of joint diseases such as osteoarthr...
|
|
WO/2010/082531A1 |
Provided are a novel salt form of a compound, which exhibits a function to inhibit the active blood coagulation factor X and is thus useful as a medicine for preventing/treating thrombotic diseases, and a crystal thereof. Provided are a ...
|
|
WO/2010/072684A1 |
The present invention relates to Norrin or a functional fragment thereof in the treatment or prevention of diseases associated with an increased TGF-beta activity. In particular, the use of said Norrin or functional fragment thereof to t...
|
|
WO/2010/064806A2 |
The present invention relates to a composition for preventing tissue adhesion which comprises a bio-compatible hyaluronic acid and a polymer compound. More specifically, the invention is a composition containing hyaluronic acid which has...
|
|
WO/2010/043106A1 |
An injectable in-situ crosslinked hydrogel and the preparation method thereof. The method comprises the step of: filling the crosslinking active solution of at least one biocompatible macromolecule into an injectable container, wherein t...
|
|
WO/2010/017598A1 |
The present invention provides an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80) and ...
|
|
WO/2010/013231A2 |
A method of modulating transplant organ size in a subject in need thereof is disclosed. The method comprising: (a) administering to the subject an agent capable of modulating an activity or expression of a coagulation factor or an effect...
|
|
WO/2010/006634A1 |
The invention relates to the field of radiation injury. More particularly, this invention relates to the protection against/prevention of and treatment of diseases caused by ionizing radiation by the use of thrombomodulin.
|
|
WO/2009/133763A1 |
Disclosed is a visible medical treatment material suitable as a material for inhibiting the adhesion in a living body, a hemostatic material and the like. The medical treatment material comprises an at least two-component crosslinkable c...
|
|
WO/2009/129374A2 |
This invention provides methods and compositions for preventing post-surgical adhesion formation based on use of an interleukin-16 (IL-16) antagonist, including an IL-16 antagonist peptide and/or an IL-16 antagonist antibody.
|
|
WO/2009/109751A1 |
The present invention provides phospholipid in a crystalline form, a method for its preparation, compositions comprising it and its use in the treatment of damaged tissue.
|
|
WO/2009/106368A1 |
The present invention relates to methods for increasing the activity of the immune system and, especially, to methods for increasing the activity of the immune system by modulation of endogenous ectophosphatase levels. According to a par...
|
|
WO/2009/104005A1 |
The invention provides the use of an unbound polyphosphate to promote chronic wound healing, in which the polyphosphate has at least 3 phosphate units. Also provided are a method of treatment and a pharmaceutical composition, both based ...
|
|
WO/2009/105165A2 |
The invention relates to improved cardioplegia solutions. The invention provides cardioplegia solutions and compositions that produce a readily reversible, rapid electrochemical arrest with minimal tissue ischaemia. The cardioplegia solu...
|
|
WO/2009/104802A1 |
The present invention relates to a compound of formula I:wherein: R1 is a hydrogen atom, F, CN, etc.; R2 is CO, SO2, etc.; R3 is a phenyl which may be substituted; X1, X2, and X3 each independently CH, N, etc. provided, however, that amo...
|
|
WO/2009/090020A1 |
The present invention relates to the use of an alginate for the production of a cross-linked, highly pure and high-molecular alginate solution (SoI) as a filler material for medical purposes, particularly for (dermatological) surgery, or...
|
|
WO/2009/080899A2 |
The present invention relates to new products, and methods, which can be used in regulating cell and tissue growth. In particular, the present invention relates to new products, and methods, which can be used for improving cell or tissue...
|
|
WO/2009/066746A1 |
It is intended to provide a material for preventing tissue adhesion which can be prepared in situ during a surgical operation to form a three-dimensional polymer construct showing a flexible structure and a high solute permeability in a ...
|
|
WO/2008/040002A9 |
The present invention generally relates to the modulation of hypoxia- inducible factor (HIF) using the compounds and methods disclosed herein. These compounds and methods can be applied to the prevention, pretreatment, and/or treatment o...
|
|
WO/2009/028559A1 |
Disclosed is a water-absorbing polymer particle with low toxicity. Specifically disclosed is a water-absorbing polymer particle which is composed of a saponified copolymer of a vinyl ester compound and an ethylenically unsaturated carbox...
|
|
WO/2009/028965A1 |
The invention provides a hydrogel suitable for use in wound healing, particularly for reducing post-surgical adhesions. The hydrogel comprises cross-linked derivatives of chitosan and dextran polymers. The hydrogel forms when solutions o...
|
|
WO/2009/012534A1 |
This application describes compositions, methods of treatment, and methods of manufacturing a medicament for reducing injury or damage to cells, tissues or organs during ischemia, reperfusion, or following ischemia or trauma. The methods...
|
|
WO/2009/005790A2 |
The present application provides sterile hyaluronic polymer compositions than are useful, e.g., as medical devices, biomedical adhesives, and sealants. Generally, provided are sterile dry compositions comprising a soluble thiol-derivatiz...
|
|
WO/2008/157323A1 |
An antimicrobial film-forming composition, an antimicrobial film, and a method of verifying the presence of an antimicrobial film. The film-forming composition can include no greater than 10 weight percent of polyvinyl alcohol, from 0.05...
|
